Lee Gary K. sold $2K of LYEL
Lee Gary K. (Chief Scientific Officer) sold 130 shares of Lyell Immunopharma, Inc. (LYEL) at $18.92 on 2026-05-11.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the officer’s open-market sale details (shares, price, total value, post-transaction holdings). This typically has limited trading impact unless unusually large or paired with other negative news.
Market read
Traders may note the sale for sentiment monitoring, but there is no new operational or financial catalyst in the text.
What to watch
The filing does not state intent beyond the transaction code; without context on total holdings, prior sales cadence, or upcoming catalysts, directional inference is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for Lyell Immunopharma, Inc.
Ticker impact
Lyell Immunopharma disclosed an officer (Chief Scientific Officer) open-market sale of 130 shares at $18.92 on 2026-05-11 via Form 4.
Low near-term impact; any reaction is likely muted and short-lived.
This is a small, single-tranche Form 4 sale by an officer with no 10b5-1 plan stated; it does not include new clinical, regulatory, or financial guidance.
Market effects
No clear sector read-through; single-company insider transaction without accompanying catalysts.
None indicated.
None indicated.
Counterpoint
Insider sales can reflect diversification or liquidity needs rather than bearish expectations, especially when not tied to a 10b5-1 plan.
Key entities
- issuerLyell Immunopharma, Inc.
Company whose insider transaction was reported on SEC Form 4.
- insiderLee Gary K.
Chief Scientific Officer who sold 130 shares in an open-market transaction.